Argatroban use in heparin-induced thrombocytopenia

Bibliography

• Surgeon General's Workshop on Deep Vein Thrombosis. May 2006. Available from: surgeongeneral.gov
   Google Scholar
• Reilly RF. The pathophysiology of immune-mediated heparin-induced thrombocytopenia. Semin Dial 2003;16(1):54-60
   PubMedGoogle Scholar
• Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996;10(4):249-58
   PubMed Web of Science ®Google Scholar
• Brieger DB, Mak KH, Kottke-Marchant K, et al. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31(7):1449-59
   PubMed Web of Science ®Google Scholar
• McKeage K, Plosker GL. Argatroban. Drugs 2001;61(4):515-22; discussion 523-4
   PubMed Web of Science ®Google Scholar
• Cleveland KW. Argatroban, a new treatment option for heparin-induced thrombocytopenia. Crit Care Nurse 2003;23(6):61-6
   PubMedGoogle Scholar
• Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96(3):846-51
   PubMed Web of Science ®Google Scholar
• Company TM. Angiomax prescribing information. Parsippany, NJ; 2007
   Google Scholar
• Pharmaceuticals B. Refludan prescribing information; 2004
   Google Scholar
• Glaxo-Smith-Kline. Argatroban prescribing information; 2007
   Google Scholar
• Okamoto S. Hijikata A. Kikumoto R, et al. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981;101(2):440-6
   PubMed Web of Science ®Google Scholar
• Kikumoto R, Tamao Y, Tezuka T, et al. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl+++) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 1984;23(1):85-90
   PubMed Web of Science ®Google Scholar
• Berry CN, Girardot C, Lecoffre C, et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb Haemost 1994;72(3):381-6
   PubMed Web of Science ®Google Scholar
• Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Blood 1998;92(6):2064-74
   PubMed Web of Science ®Google Scholar
• Swan SK, St Peter JV, Lambrecht LJ, et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000;20(7):756-70
   PubMed Web of Science ®Google Scholar
• Izawa OKM, Komatsu T, Iida S. Pharmacokinetic studies of argatroban (MD-805) in human: concentrations of argatroban and its metabolites in plasma, urine and feces during and after drip intravenous infusion. Jpn Pharmacol Ther 1986;14:251-63
   Google Scholar
• Nagasawa HFK, Hada M, Takahashi E, et al. Phase one study of synthetic anti-thrombin agent (MD-805) single and multiple administration studies. Jpn J Clin Pharmacol Ther 1981;12:359-75
   Google Scholar
• Clarke RJ, Mayo G, FitzGerald GA, et al. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991;83(5):1510-8
   PubMed Web of Science ®Google Scholar
• Walenga JM, Fasanella AR, Iqbal O, et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999;25(Suppl 1):61-6
   PubMedGoogle Scholar
• Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001;85(3):435-40
   PubMed Web of Science ®Google Scholar
• Hiatt BK, MacFarlane DE, Hursting MJ. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated International Normalized Ratio (INR). J Thromb Thrombolysis 2005;19(3):183-8
   PubMedGoogle Scholar
• Smythe MA, Warkentin TE, Stephens J, et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 2002;71:50-2
   PubMed Web of Science ®Google Scholar
• Walenga JMKM, Lewis BE, Pifarre R. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemostasis 1996;2(Suppl 1):S21-7
   Web of Science ®Google Scholar
• Song X, Huhle G, Wang L, et al. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999;100(14):1528-32
   PubMed Web of Science ®Google Scholar
• Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000;96(7):2373-8
   PubMed Web of Science ®Google Scholar
• Harenberg J, et al. Re-exposure to recombinant (r)-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia. Br J Haematol 2000;109(2):360-3
   PubMedGoogle Scholar
• Lewis BE, WD, Zehnder JL, Barton JC; for the ARG-911/915/915x Investigators. Argatroban reexposure in patients with heparin-induced thrombocytopenia [abstr]. Blood 2000a;96(Part 1):52a
   Google Scholar
• Lewis BCM, Moses J, Matthai W; for the ARG-216/310/311 Investigators. Argatroban anticoagulation during initial and repeat percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Am J Cardiol 2000b;86(Suppl 8A):14i
   Google Scholar
• Soff GA, S-B. Pers Commun; Dec 27th 2007
   Google Scholar
• Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103(14):1838-43
   PubMed Web of Science ®Google Scholar